Connect with us

Technology

Quantum Computing Inc. Reports Second Quarter and First Half 2024 Financial Results

Published

2 years ago

on

HOBOKEN, N.J., Oct. 2, 2024 /PRNewswire/ — Quantum Computing Inc. (“QCi” or the “Company”) (Nasdaq: QUBT), an innovative, integrated photonics and quantum optics technology company, today released financial results for the three- and six-month periods ended June 30, 2024, which contain restated financial results for the quarterly periods ended June 30, 2023.

Dr William McGann, Chief Executive Officer of QCi, commented, “During the first half of 2024, we strengthened our position in the quantum computing landscape. Our progress on establishing our U.S.-based Thin Film Lithium Niobate (TFLN) foundry is proceeding well, marking a critical step toward positioning QCi as a leader in the growing optical chip market. Our partnerships continued to evolve, highlighted by our successful product sale to Johns Hopkins University and ongoing collaboration with NASA. I’m also pleased to announce that with the filing of these financial results, we have taken key steps to regain compliance with Nasdaq and are now caught up with our Securities and Exchange Commission (SEC) reporting requirements. Like some other companies that experienced delays due to forced auditor transitions, we’ve navigated this process effectively while ensuring adherence to best practices. We are now well-positioned to continue advancing our mission.”

Second Quarter 2024 Financial Highlights:

Second quarter 2024 revenues totaled approximately $183,000 (32% gross margin) compared to $112,000 (54% gross margin) generated in the second quarter 2023. The increase in revenues was due to increased contractual sales. The decrease in gross margin was nearly entirely the result of revenue in the current period being primarily comprised of customized research and development as compared to consulting services revenue in the prior period.Second quarter 2024 operating expenses totaled $5.3 million compared to the previous year’s second quarter operating expenses of $7.0 million. The 24% period-over-period decrease is primarily a result of the Company’s disciplined strategy to minimize general and administrative expenses as well as net reductions in stock-based compensation.The Company reported a net loss available to common stockholders of $5.2 million, or $(0.06) per basic share for the second quarter of 2024, compared to a net loss available to common stockholders of $7.6 million or $(0.12) per basic share for the same period of the previous year.Total assets at June 30, 2024 were $76.0 million, increasing from $74.4 million at December 31, 2023. Cash and cash equivalents at June 30, 2024 increased $0.5 million from year-end 2023 to $2.5 million. Subsequent to the close of the quarter, the Company raised net proceeds of $7.0 million in a secured convertible debt financing.Total liabilities at June 30, 2024 were $3.6 million, a decrease of approximately $2.1 million compared to year-end 2023, driven primarily by the Company’s monthly repayment of its unsecured debt, which was paid in full in the first quarter of 2024, and sizable reduction in accrued expenses reflecting the issuance of restricted stock grants.As of June 30, 2024, the Company had shareholders’ equity totaling $65.5 million.

Second Quarter 2024 Operational Highlights

Successful Quantum LiDAR Prototype Sale: QCi executed the sale of a quantum LiDAR prototype to Johns Hopkins University for $200,000. This sale marked a significant advancement in underwater LiDAR technology and showcases the commercial potential of QCi’s quantum solutions across diverse applications.Enhanced Sales Strategy: QCi appointed Richard Nelson as Senior Vice President of Business Development and Pouya Dianet as Director of TFLN Optical Chip Sales to accelerate market penetration and expand global sales of QCi’s quantum technologies.TFLN Foundry Progress: The Company continues to advance its strategic initiative to establish the first U.S.-based TFLN fabrication facility in Tempe, Arizona, a key element of QCi’s long-term strategy to become a leader in the optical chip market, and to secure offtake agreements for future chip sales from the foundry.Subsequent to the Quarter: In line with the Company’s initiative to expand its partnerships with government agencies and laboratories, QCi announced the extension of its Cooperative Research and Development Agreement (CRADA) with the Los Alamos National Laboratory (LANL). This strategic collaborative agreement focuses on QCi’s new entropy quantum optimization machine, Dirac-3, and its capabilities to quickly and efficiently solve highly complex problems associated with quantum simulations, social networks, protein structure prediction, and telecommunications.

Additionally, the Company filed with the SEC its Form 10-Q for the quarterly period ending March 31, 2024, which contains restated financial results for the three-month period ended March 31, 2023. As previously disclosed, following the entry of a cease-and-desist order by the SEC against the Company’s former auditor, BF Borgers CPA PC, the Company engaged a new independent registered public accounting firm, BPM LLP, to reaudit 2023 and 2022 financial results and the quarterly financial results released today.  While the auditor transition was the primary reason for the delay in our March 31, 2024 and June 30, 2024, quarterly filings, we do not expect any further delays going forward.

Quantum Computing Inc. (QCi) (Nasdaq: QUBT) is an innovative, integrated photonics company that provides accessible and affordable quantum machines to the world today. QCi products are designed to operate at room temperature and low power at an affordable cost. The Company’s portfolio of core technology and products offer unique capabilities in the areas of high-performance computing, artificial intelligence and cybersecurity as well as remote sensing applications.

QUANTUM COMPUTING INC.

Condensed Consolidated Balance Sheets

(Unaudited, in thousands, except par value data)

 

June 30,

December 31,

2024

2023

  Assets

  Current assets

     Cash and cash equivalents

$

2,526

$

2,059

     Accounts receivable

56

65

     Inventory

266

73

     Loans receivable, net of provision for credit losses of $295 and $279

295

279

     Prepaid expenses and other current assets

272

180

Total current assets

3,415

2,656

Property and equipment, net

5,387

2,870

Operating lease right-of-use assets

923

1,051

Intangible assets, net

10,524

12,076

Goodwill

55,573

55,573

Other non-current assets

133

129

Total assets

$

75,955

$

74,355

Liabilities and Stockholders’ Equity

Current liabilities

       Accounts payable

$

1,672

$

1,462

       Accrued expenses

327

639

       Financial liabilities, net of issuance costs

–

1,925

       Deferred revenue

104

–

       Other current liabilities

790

786

Total current liabilities

2,893

4,812

Operating lease liabilities

708

840

Total liabilities

3,601

5,652

Contingencies (see Note 10)

Mezzanine equity

6,829

–

Stockholders’ equity

     Preferred stock, $0.0001 par value, 1,550 shares Series A Preferred authorized; 1,241  

          and 1,490 shares issued and outstanding as of June 30, 2024 and December 31,

          2023, respectively; 3,080 shares of Series B Preferred Stock authorized; no shares

          issued and outstanding as of June 30, 2024 and December 31, 2023

–

–

     Common stock, $0.0001 par value, 250,000 shares authorized; 94,416 and 77,451  

          shares issued and outstanding as of June 30, 2024 and December 31, 2023,

          respectively

9

8

     Additional paid-in capital

209,086

200,635

     Accumulated deficit

(143,570)

(131,940)

Total stockholders’ equity

65,525

68,703

Total liabilities and mezzanine and stockholders’ equity

$

75,955

$

74,355

 

QUANTUM COMPUTING INC.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except per share data)

Three Months Ended

Six Months Ended

June 30,

June 30,

2024

2023

2024

2023

(Restated)

(Restated)

Total revenue

$

183

$

112

$

210

$

233

Cost of revenue

125

51

141

107

Gross profit

58

61

69

126

Research and development

2,094

2,466

4,315

4,650

Sales and marketing

429

385

880

812

General and administrative

2,802

4,168

6,459

7,718

Operating expenses

5,325

7,019

11,654

13,180

Loss from operations

(5,267)

(6,958)

(11,585)

(13,054)

Non-operating income (expense)

Interest and other income

73

61

110

93

Interest expense, net

–

(537)

(155)

(963)

Change in value of warrant liability

–

17

–

370

Loss before income tax provision

(5,194)

(7,417)

(11,630)

(13,554)

Income tax provision

–

–

–

–

Net loss

(5,194)

(7,417)

(11,630)

(13,554)

Less: Series A convertible preferred stock dividends

–

(215)

–

(431)

Net loss available to common stockholders

$

(5,194)

$

(7,632)

$

(11,630)

$

(13,985)

Loss per share – basic and diluted

$

(0.06)

$

(0.12)

$

(0.13)

$

(0.23)

Weighted average shares used in computing net loss per 

common share – basic and dilutive

93,550

62,667

87,185

60,832

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/quantum-computing-inc-reports-second-quarter-and-first-half-2024-financial-results-302266104.html

SOURCE Quantum Computing Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Kakunin Announces Cryptographic Compliance Shield for Google Gemini and OpenAI Agent Ecosystems

Published

3 hours ago

on

June 14, 2026

By

SaaS Compliance Leader Launches First-Class SDK Integrations for Google Antigravity, OpenAI Swarm, and OpenAI Assistants API to Meet Strict MiCA and EU AI Act Standards.

LONDON, June 13, 2026 /PRNewswire-PRWeb/ — Kakunin, the leading compliance infrastructure platform for autonomous AI agents, today announced the release of first-class SDK integrations for Google Antigravity SDK, OpenAI Swarm, and the OpenAI Assistants API.

Autonomous agents are executing high-value, real-world tasks—but without strict boundaries, they represent a massive security risk,” said Palash Bagchi, Founder, at Kakunin.

As organizations move autonomous AI agents from sandboxes to production, securing the tools they run has become a critical operational hurdle. The new integrations allow developers to cryptographically secure and audit agent actions in real time, meeting the strict requirements of upcoming regulations like the EU AI Act and MiCA.

Preventing Agent Drift at the Tool Layer

Instead of relying on prompt engineering or system instructions—which are susceptible to jailbreaks—Kakunin secures agent tool execution at the cryptographic layer:

Pre-Flight Scope Verification: Validates that an agent possesses the required permission scope (e.g., trade.execute, file.write) before executing local code.Active-Agent Enforcement: Dynamically halts execution if the agent’s underlying X.509 certificate has been revoked or suspended.Tamper-Evident Auditing: Automatically logs session starts, prompts, responses, tool successes, and error anomalies.

Ecosystem Compatibility out of the Box

The new releases bring seamless, code-first integrations to the industry’s leading agent frameworks:

Google Antigravity SDK: Hook-based runtime protection that automatically secures Gemini-powered tool workflows.OpenAI Swarm: A lightweight class wrapper (KakuninSwarm) that dynamically gates multi-agent handoffs and task executions.OpenAI Assistants API: A polling-loop helper (handle_assistants_requires_action) that streamlines safety checks and tool output formatting in a single call.

Beyond these core OpenAI and Google environments, the new releases also extend Kakunin’s cryptographic shield to the broader agent development community. Out-of-the-box templates and shims are now available for LangChain (KakuninToolGuard), LlamaIndex (KakuninFunctionToolGuard), CrewAI (KakuninCrewAgent), and AutoGen (KakuninConversableAgent), alongside native middlewares for Next.js API routes and raw client libraries for Go, TypeScript, and Python.

“Autonomous agents are executing high-value, real-world tasks—but without strict boundaries, they represent a massive security risk,” said Palash Bagchi, Founder, at Kakunin. “By bringing cryptographic X.509 validation directly to Google’s and OpenAI’s agent loops, we are giving developers the peace of mind to deploy agents in highly regulated environments like fintech and healthcare.”

Availability

The new SDK integrations are available immediately:

Python Package: Available on PyPI via pip install kakunin.Playground Notebooks: Developers can test the integrations in 1-click via the official OpenAI Cookbook and Google Gemini Cookbook.Reference Samples: Available on the public Kakunin Samples Repository.

To learn more about securing your autonomous agent workflows, visit kakunin.ai/docs. or visit Conversational GTM for more enquiries.

Media Contact
Palash Bagchi, Immortal Reality PA LLC, 1 4125437290, ai@kakunin.ai, https://www.kakunin.ai/

View original content to download multimedia:https://www.prweb.com/releases/kakunin-announces-cryptographic-compliance-shield-for-google-gemini-and-openai-agent-ecosystems-302798798.html

SOURCE Kakunin

Continue Reading

Technology

District Taco Kicks Off The Summer’s Biggest Soccer Event with Free Delivery Offer

Published

10 hours ago

on

June 13, 2026

By

App Users can enjoy District Taco at home with free delivery during the world’s biggest soccer tournament.

WASHINGTON, June 13, 2026 /PRNewswire-PRWeb/ — District Taco is bringing the excitement of the world’s biggest soccer tournament straight to fans’ homes with a special promotion designed to make game-day meals even more convenient.

This promotion makes it easier and more affordable to enjoy District Taco delivered right to your door so you don’t miss a moment of the action!

From June 11 through July 19, guests who order delivery through the District Taco app can use promo code ‘SOCCER26’ to receive $5 off their order, effectively offsetting the standard delivery fee and creating a free delivery experience.

Whether cheering on a favorite team, hosting a watch party, or enjoying the match from the couch, fans can enjoy District Taco’s fresh, made-to-order menu without leaving home or the extra delivery cost. “We know fans will be gathering throughout the tournament to watch some of the most exciting matches in the world,” said Osiris Hoil, CEO of District Taco. “This promotion makes it easier and more affordable to enjoy District Taco delivered right to your door so you don’t miss a moment of the action!”

The promotion is part of District Taco’s broader effort to drive digital engagement and app use. Here are the campaign details:

Enter Promo Code: ‘SOCCER26’ when placing the order in-appOffer: $5 off delivery ordersAvailable: June 11 through July 19Valid on: District Taco app delivery orders only (not third-party platforms)

Guests can download the District Taco app here for Apple users and here for Android users!

About District Taco

In 2009, two neighbors got together over some homemade chips, salsa and guacamole and decided to launch District Taco as a food cart. Since then, District Taco has opened multiple locations in Virginia, Maryland, New Jersey, New York, Pennsylvania, Florida, and Washington, DC. Their mission is to serve quality – Yucatán style – Mexican food that is fresh, simple, and healthful, with a fully customizable menu that includes vegetarian, vegan and gluten-free options. At District Taco, food is made fresh daily from the highest quality ingredients. They strive to limit their impact on the environment by serving in environmentally friendly packaging where possible. For more information about District Taco or their menu, and to download the app, visit districttaco.com or follow @districttaco across socials.

Media Contact

Raquel Robinson, District Taco, 1 5712657573, raquel.robinson@districttaco.com, districttaco.com

View original content to download multimedia:https://www.prweb.com/releases/district-taco-kicks-off-the-summers-biggest-soccer-event-with-free-delivery-offer-302799507.html

SOURCE District Taco

Continue Reading

Technology

MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations

Published

15 hours ago

on

June 13, 2026

By

GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life sciences, is showcasing its latest advancements in sequencing, automation and clinical genomics at the European Society of Human Genetics (ESHG) 2026 Conference in Gothenburg, Sweden.

At Booth 352, MGI welcomes researchers, clinicians, laboratory leaders and industry partners to explore its comprehensive portfolio of sequencing and automation solutions while unveiling new initiatives designed to strengthen collaboration across the genomics ecosystem.

Advancing Clinical Genomics Through Partnership

A key highlight of ESHG 2026 is the launch of the MGI NGS Partner Enablement Program, a new initiative designed to connect diagnostic developers, assay providers and laboratory partners seeking to build validated clinical workflows on MGI sequencing platforms.

The program aims to accelerate the development and adoption of regulated next-generation sequencing (NGS) applications by fostering collaborations that simplify workflow implementation, reduce time-to-market and support broader access to precision medicine solutions.

“Clinical genomics is increasingly dependent on strong partnerships across the value chain,” said Fang Chen, General Manager Europe & Africa at MGI. “With the launch of our NGS Partner Enablement Program, we are creating a collaborative framework that brings together assay developers, software providers, automation partners and clinical laboratories to accelerate access to high-quality genomic testing.”

Expanding Automation Capabilities Through OEM Collaborations

At ESHG 2026, MGI is also announcing new Original Equipment Manufacturer (OEM) partnership opportunities on MGI’s DE Bundles (integrated library preparation and sequencing platform), bringing turnkey automation to global partners. The DE Bundle includes the current D4+E25 combination, as well as the new D16 paired with the E25 featuring a new 50M flow cell.

The D16, which will be launched later this year, is a benchtop, mid-to-low throughput library prep system and the upgraded successor to the D4. Retaining the fully enclosed contamination control system, it integrates a single-channel robotic pipetting module to maximize automation. With two sample preparation cartridges each processing 8 samples, the D16 delivers significantly higher throughput. The D16 and E25 systems provide flexible and scalable automation solutions for library construction, sequencing, bioinformatics analysis, streamlining the entire laboratory workflow.

Through this open OEM framework, MGI is enabling customers and solution providers to integrate proven automation technologies into customized workflows tailored to specific clinical and research applications. The OEM program reflects MGI’s commitment to building an open ecosystem that empowers laboratories to increase efficiency, improve standardization and accelerate scientific discovery.

“We are excited to expand the opportunities available to our OEM partners by providing access to the D16 platform, enabling the development of truly walkaway solutions that simplify and automate complex laboratory workflows,” said Wim Vervaeke, OEM Director at Europe & Africa at MGI. “Our innovations, including the PrepALL, E25, and G99, have already sparked new partnerships across the life sciences ecosystem. By combining MGI’s automation expertise with the specialized capabilities of our partners, we are creating integrated solutions that deliver maximum value, efficiency, and convenience for end users.”

Corporate Satellite Symposium Highlights Clinical Genomics, Precision Oncology and Spatial Multi-Omics

As part of ESHG 2026, MGI hosted its Corporate Satellite Symposium, Advancing Diagnostics: From Clinical Implementation to Biomarker Discovery, bringing together leading experts from across Europe to showcase how advanced genomic technologies are being translated into real-world clinical and research impact. The symposium highlighted applications spanning clinical oncology diagnostics, pharmacogenomics, and spatial multi-omics.

Dr. Raquel T. Lima from IPATIMUP (Portugal) presented the clinical value of RNA sequencing for detecting actionable gene fusions in solid tumours, improving diagnostic yield and supporting precision oncology decision-making. Prof. Dr. Andreas Braun from University Hospital Schleswig-Holstein (Germany) shared how spatial biology technologies map the tumour microenvironment in melanoma, revealing tumour heterogeneity, cellular interactions, and mechanisms associated with disease progression and treatment response. Dr. Andrea Conti from BMR Genomics (Italy) explored the opportunities of whole genome sequencing for pharmacogenetic marker evaluation, highlighting how comprehensive genomic approaches can support the implementation of personalised medicine through improved identification of clinically relevant variants.

Together, the presentations demonstrated how genomic and multi-omics technologies are advancing clinical diagnostics, translational oncology research, and precision medicine, while highlighting the growing role of sequencing in delivering actionable insights across healthcare and biomedical research.

Comprehensive Solutions for Genomics and Multi-Omics Research

Visitors to the MGI booth can explore the company’s comprehensive portfolio of sequencing and automation technologies supporting applications across human genetics, oncology, reproductive health, population genomics and multi-omics research.

Highlighting strong market adoption, MGI is showcasing the T7+, its ultra-high-throughput sequencing platform at the conference. Following its official launch for the Europe and Africa region at Analytica 2026 in Munich, the T7+ has gained significant momentum, with 27 units installed worldwide as of the end of 2025. From benchtop to ultra-high-throughput sequencing platforms, as well as advanced laboratory automation solutions, MGI continues to support laboratories seeking high-performance, scalable and cost-effective genomics workflows.

“Our mission extends beyond delivering innovative technologies,” said Dr. Christian Zimmerman, VP Sales Europe & Africa at MGI. “We are focused on building a complete ecosystem that enables our customers to transition seamlessly from research to clinical implementation. The partnerships and initiatives we are launching at ESHG 2026 demonstrate our commitment to making genomic technologies more accessible, integrated and impactful.”

Driving the Future of Precision Medicine in Europe

Europe remains a strategic region for MGI, with growing adoption of genomic technologies across research institutions, healthcare systems and national population initiatives.

Through continued investment in sequencing innovation, automation, clinical partnerships and collaborative ecosystem development, MGI is helping accelerate the transition toward more precise, data-driven healthcare.

As genomics increasingly becomes integrated into routine clinical practice, MGI remains committed to providing the technologies and partnerships necessary to support the next generation of precision medicine.

About MGI

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers of a full-stack product portfolio that spans three core segments: SEQ ALL (short- and long-read sequencing), GLI (Generative Lab Intelligence), and Multi-Omics. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

To learn more, please visit MGI Tech, LinkedIn, X, Instagram, and YouTube.

 

View original content:https://www.prnewswire.co.uk/news-releases/mgi-tech-showcases-expanding-genomics-ecosystem-at-eshg-2026-with-new-ivd-partnering-program-and-oem-collaborations-302799622.html

Continue Reading

Trending